Biotech | October 11, 2021
Astra’s antibody injection trial indicates it can prevent and treat Covid-19
AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial
AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
Research collaboration covers multiple antibody research programs
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Subscribe To Our Newsletter & Stay Updated
